Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/8219
Full metadata record
DC FieldValueLanguage
dc.contributor.authorDimitriou, A. A.en
dc.contributor.authorStathopoulos, P.en
dc.contributor.authorMitsios, J. V.en
dc.contributor.authorSakarellos-Daitsiotis, M.en
dc.contributor.authorGoudevenos, J.en
dc.contributor.authorTsikaris, V.en
dc.contributor.authorTselepis, A. D.en
dc.date.accessioned2015-11-24T16:40:01Z-
dc.date.available2015-11-24T16:40:01Z-
dc.identifier.issn0953-7104-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/8219-
dc.rightsDefault Licence-
dc.subjectalpha(iib)beta(3) receptoren
dc.subjectcell-penetrating conjugatesen
dc.subjectplatelet activation inhibitorsen
dc.subjecttat-conjugated peptidesen
dc.subjectbeta(3) cytoplasmic domainen
dc.subjectarginine-rich peptidesen
dc.subjectcytoplasmic domainen
dc.subjectinside-outen
dc.subjectfibrinogen bindingen
dc.subjectoutside-inen
dc.subjectbeta(3)en
dc.subjectsubuniten
dc.subjecttailen
dc.subjectmembraneen
dc.subjectalpha(iib)-subuniten
dc.titleInhibition of platelet activation by peptide analogs of the beta(3)-intracellular domain of platelet integrin alpha(IIb)beta(3) conjugated to the cell-penetrating peptide Tat(48-60)en
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.primaryDoi 10.3109/09537100903324219-
heal.identifier.secondary<Go to ISI>://000272719400002-
heal.identifier.secondaryhttp://informahealthcare.com/doi/abs/10.3109/09537100903324219-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Θετικών Επιστημών. Τμήμα Χημείαςel
heal.publicationDate2009-
heal.abstractActivation of the platelet integrin-receptor alpha(IIb)beta(3) is the final pathway of platelet aggregation, regardless of the initiating stimulus. Many studies suggest that there are several cytoplasmic proteins such as talin and beta(3)-endonexin that bind to N(744)PLY(747) and N(756)ITY(759) motif of the beta(3) cytoplasmic tail and play the major role in the receptor activation. In this study, we investigated the role of the membrane distal region of human beta(3) cytoplasmic tail and specifically the N(743)NPLYKEA(750) and T(755)NITYRGT(762) sequence that contains an NXXY motif, in platelet aggregation, secretion, alpha(IIb)beta(3) activation (PAC-1 binding) and fibrinogen binding. We synthesized two peptides corresponding to the above sequences as well as their conjugates with the Tat(48-60) cell-penetrating peptide. The capability of conjugates to penetrate the platelet membrane was investigated with confocal laser scanning microscopy using carboxyfluorescein (CF)-labeled peptides. Our results showed that the conjugated with the Tat(48-60) sequence peptides penetrate the platelet membrane and inhibit platelet aggregation in both PRP and washed platelets in a dose-dependent manner. The Tat-beta(3)743-750 conjugate exhibited similar inhibitory activity in PRP and in washed platelets whereas the Tat-beta(3)755-762 conjugate was more potent inhibitor of aggregation in washed platelets than in PRP. Both conjugated peptides were also able to inhibit P-selectin membrane expression as well as PAC-1 and fibrinogen binding to the platelets, the Tat-beta(3)755-762 conjugate being more potent than Tat-beta(3)743-750. The Tat(48-60) peptide and the peptides beta(3)743-750 and beta(3)755-762, which were not conjugated to the Tat(48-60) sequence, did not exhibit any inhibitory effect on the above parameters. In conclusion, the present study shows for the first time that the peptide analogs of the intracellular domain of the beta(3) subunit beta(3)743-750 and beta(3)755-762 conjugated to the cell-penetrating peptide Tat(48-60) are capable of penetrating the platelet membrane and expressing biological activity by inhibiting the activation of alpha(IIb)beta(3), the fibrinogen binding to the activated receptor as well as platelet aggregation. Further studies are necessary to support whether such conjugated peptides may be useful tools for the development of potent antiplatelet agents acting intracellularly through the platelet integrin alpha(IIb)beta(3).en
heal.journalNamePlateletsen
heal.journalTypepeer reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά). ΧΗΜ

Files in This Item:
There are no files associated with this item.


This item is licensed under a Creative Commons License Creative Commons